---
figid: PMC7493839__12935_2020_1546_Fig3_HTML
figtitle: Application of CRISPR-Cas9 in construction of TCR and CAR T-cells
organisms:
- Escherichia coli K-12
- Streptococcus pyogenes
- Synechocystis sp.
- Legionella pneumophila
- Thermus thermophilus
- Streptococcus agalactiae
- Rhodococcus jostii RHA1
- Marinomonas mediterranea
- Thioalkalivibrio sp.
- Shewanella putrefaciens CN-32
- Rippkaea orientalis PCC 8801
- Neisseria lactamica 020-06
- Bacillus thuringiensis HD-771
- Ruminococcus sp. N15.MGS-57
- Candidatus Micrarchaeum sp. ARMAN-1
- Oleiphilus sp.
- Francisella cf. novicida Fx1
- Hepatitis B virus
- Human papillomavirus
- Human papillomavirus type 16
- Human alphaherpesvirus 2
- Homo sapiens
- Mus musculus
- Molva molva
- uncultured Cyanothece sp.
- NA
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
pmcid: PMC7493839
filename: 12935_2020_1546_Fig3_HTML.jpg
figlink: pmc/articles/PMC7493839/figure/Fig3/
number: F3
caption: Application of CRISPR-Cas9 in construction of TCR and CAR T-cells. a CRISPR-Cas9
  is used for the creation of allogeneic T-cells by depletion of endogenous TCR and
  MHC class I genes through the NHEJ pathway. b Inhibition of immune checkpoint pathways
  such as PD-1, CTLA4, LAG3, TIM3, and FAS is accessible through the employment of
  CRISPR-Cas9 to disrupt the related receptors on T-cells. c Installation of transgenic
  TCR or CAR into T-cells through HDR-mediated knock-in potential of CRISPR-Cas9.
  TCR and CAR can be inserted in between of a locus of interest. For instance, the
  introduction of TCR or CAR among TRAC locus in order to simultaneous knockout of
  endogenous TCR and establishment of recombinant TCR or CAR leads to homogenous expression
  of cassette and also the elimination of mutation probability, which is common among
  vector integration methods. d Loss of function screening is another application
  of CRISPR, in which effect of T-cell function on cancer immunotherapy in presence
  or absence of a gene is investigated and the results may use for development of
  further immunotherapeutic approaches
papertitle: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer
  immunotherapy.
reftext: Seyed Mohammad Miri, et al. Cancer Cell Int. 2020;20:456.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.5012791
figid_alias: PMC7493839__F3
figtype: Figure
redirect_from: /figures/PMC7493839__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7493839__12935_2020_1546_Fig3_HTML.html
  '@type': Dataset
  description: Application of CRISPR-Cas9 in construction of TCR and CAR T-cells.
    a CRISPR-Cas9 is used for the creation of allogeneic T-cells by depletion of endogenous
    TCR and MHC class I genes through the NHEJ pathway. b Inhibition of immune checkpoint
    pathways such as PD-1, CTLA4, LAG3, TIM3, and FAS is accessible through the employment
    of CRISPR-Cas9 to disrupt the related receptors on T-cells. c Installation of
    transgenic TCR or CAR into T-cells through HDR-mediated knock-in potential of
    CRISPR-Cas9. TCR and CAR can be inserted in between of a locus of interest. For
    instance, the introduction of TCR or CAR among TRAC locus in order to simultaneous
    knockout of endogenous TCR and establishment of recombinant TCR or CAR leads to
    homogenous expression of cassette and also the elimination of mutation probability,
    which is common among vector integration methods. d Loss of function screening
    is another application of CRISPR, in which effect of T-cell function on cancer
    immunotherapy in presence or absence of a gene is investigated and the results
    may use for development of further immunotherapeutic approaches
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - LAG3
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - TRAC
  - NCOR2
  - SNCA
  - SPATA2
  - CTLA4
  - FAS
  - FASN
  - HAVCR2
  - CASR
  - CXADR
  - PRKAR1A
  - SPG7
  - NR1I3
  - TRIM13
  - CXADRP1
  - MARVELD2
  - GATA3
  - IL21
  - IL22
  - B2M
  - Trav6-3
  - Lag3
  - Pdcd1
  - Trac
  - Abcg5
  - Ctla4
  - Fas
  - Fasn
  - Havcr2
  - Nr1i3
  - Casr
  - Cxadr
  - Rcvrn
  - Trim13
  - Arr3
  - Tcp1
  - Marveld2
  - Il21
  - B2m
  - trac
  - fas
  - havcr2
  - cxadr
  - carmil1
  - hdr
  - il21
  - b2m
  - b2ml
  - TCR
---
